Ra Capital Management, L.P. Sells 149,625 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 149,625 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $0.37, for a total value of $55,361.25. Following the completion of the sale, the insider owned 331,414 shares in the company, valued at $122,623.18. The trade was a 31.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. sold 128,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.39, for a total value of $50,220.30.
• On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $68,176.40.
• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Down 4.4%

HOWL stock opened at $0.34 on Thursday. The stock has a market capitalization of $16.72 million, a PE ratio of -0.28 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 12-month low of $0.34 and a 12-month high of $2.38. The stock’s 50 day simple moving average is $0.62 and its 200 day simple moving average is $0.70.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. On average, research analysts predict that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HOWL shares. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings cut Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Werewolf Therapeutics presently has a consensus rating of “Hold” and an average price target of $3.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE lifted its holdings in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after buying an additional 221,766 shares during the period. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at $409,000. Finally, Citadel Advisors LLC bought a new position in shares of Werewolf Therapeutics during the 3rd quarter valued at $304,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.